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Introduction
Cryopyrin-associated periodic syndromes (CAPS) are
dominantly inherited autoinflammatory diseases (AD)
caused by NLRP3 mutations. They include different
phenotypes (FCAS, Muckle-Wells syndrome, and CINCA/
NOMID) with different severity, usually as childhood
onset fever and urticarial-like rash. In the last years, the
clinical picture of CAPS is growing with other manifesta-
tions than fever, urticaria, or sensorineural deafness.
Objectives
To communicate the clinical picture, genetic mutation,
therapeutic approach and follow-up of five patients from
three generations of the same pedigree with late symptoms
onset (at fourth decade of life) diagnosed from the study of
urinary bladder AA-amyloidosis of the oldest member.
Methods
Review of clinical file of the 5 involved patients from diag-
nosis until January 2013. Data studied included: onset and
diagnosis age, past medical history, clinical, laboratory,
pathologic and genetic data, treatment onset, clinical and
laboratory evolution and adverse effects related to therapy.
Results
71 yo. male was referred to Internal Medicine Service of
Vall Hebron Hospital in June 2010 due to nephrotic syn-
drome and haemorraghic cystitis. A urinary bladder and
rectal biopsies showed Congo-red deposits stained with
antiamyloid A antibody. Patient’s medical history revealed
self-limited episodic palindromic monoarthritis, and sen-
sorineural hypoacusia since mid-thirties without recurrent
fever or skin rash. ESR, CRP and serum A-amyloid protein
(SAA) were elevated. Genetic study for AD identified a p.
Ala-439-Thr NLRP3 mutation. Four family members,
-3 adults (2 ♂/1♀) and 1 child (12 yo ♀)-, shared this
mutation. All 3 adults presented adult-onset sensorineural
deafness and SAA elevation; the two males also refered
recurrent pericarditis and monoarthritis from mid-
twenties on. Off-label treatment with rIL-1RA anakinra
for symptomatic patients was considered a cost-effective
option to canakinumab, the approved drug for CAPS.
Early clinical remission, normalization of SAA, ESR and
CRP and deafness stability was achieved. Index case 24-h
proteinuria 20 months after anakinra was <500 mg.
Anakinra adverse effects were minor local reaction at
injection site (all patients) and transient alopecia in 1 adult
female patient. After 24 months of anakinra, patients are
asymptomatic. The child also remains asymptomatic since
diagnosis.
Conclusion
CAPS spectrum is still in evolution. These patients’ phe-
notype was remarkable by late disease onset, reactive AA
amyloidosis as haemorraghic cystitis and recurrent palin-
dromic arthritis and pericarditis without urticarial-like
skin rash or fever. Otherwise, anakinra proved to be an
effective treatment in this CAPS serie. CAPS must be kept
in mind for familiar sensorineural loss with AA amyloido-
sis and/or relapsing pericarditis or arthritis, even in adults.
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